Business Context and Reporting Period
This Form 6-K filing by Prima BioMed Ltd (now Immutep Ltd) is dated November 20, 2017. The document serves as a report of a foreign private issuer under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The primary purpose of this filing is to announce the official change of the registrant's name from Prima BioMed Ltd to Immutep Ltd.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate announcement regarding a name change and does not contain financial statements or performance data.
Material Changes
The material change disclosed in this filing is the corporate name change from Prima BioMed Ltd to Immutep Ltd. No financial or operational changes are detailed in this specific report.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the procedural announcement of the name change.
Investor Verification Checklist
- Verify the effective date of the name change from Prima BioMed Ltd to Immutep Ltd.
- Confirm the updated ticker symbol and trading status under the new name.
- Review subsequent filings (e.g., Form 20-F) for the first financial report issued under the Immutep Ltd name.
- Check for any related press releases detailing the strategic rationale behind the rebranding.